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Radioiodine is efficiently concentrated by tissues expressing the human sodium iodide symporter (hNIS). 
The aim of this study was to analyze the effects of 131I on acute cardiac allograft rejection after hNIS ex-
vivo gene transfer in a rat model of cardiac allotransplantation. 
Methods 
Hearts from Brown Norway rats were perfused ex vivo either with UW solution (n=9) or with UW solution 
containing 1 x 109 pfu/ml adenovirus 5+NIS (Ad-NIS) (n=18). Donor hearts were transplanted 
heterotopically into the abdomen of Lewis rats and recipients were treated on post operative day 3 with 
either 15,000 µCi 131I or saline. The hearts were explanted when no longer beating and were evaluated 
histologically for evidence of rejection and other changes. 
Results 
Grafts perfused with the Ad-NIS vector survived significantly longer in recipients injected with 131I 
(11.3±1.9 days) compared to control animals not treated with 131I (5.7±0.65 days; p<0.001). 131I treatment 
did not prolong graft survival in recipients of hearts that were not perfused with Ad-NIS (5.5±1.0 vs 
5.3±0.8 days). In Ad-NIS 131I treated transplants, the level of myocardial damage on day 6 after surgery, 
when control hearts rejected, was significantly lower (60.8±28.0 vs 99.7±0.8; p<0.05). 
Conclusions 
This study indicates that 131I, after NIS gene transfer, can effectively prolong cardiac allograft survival. To 
our knowledge, this is the first report of the use of NIS-targeted 131I therapy in cardiac transplantation. 
Further studies are required to determine the mechanism of this effect and its potential for clinical 
application. 
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 In the field of organ transplantation, maintenance of a functional allograft requires life-long 
immunosuppression to prevent rejection by the immune system. Currently used immunosuppressive 
drugs are associated with significant side effects including renal toxicity, dyslipidemia, diabetes and 
increased risk of infections and malignancies.  
 Gene therapy opens up the possibility of augmenting the effectiveness of immunosuppression or 
ameliorating the toxic effects of current immunosuppressive agents in the setting of solid organ 
transplantation, because it can be carried out ex-vivo in the donor organ under well-controlled conditions 
immediately before transplantation, and because potentially therapeutic agents can be introduced 
directly into the graft, where it may have its greatest effect and least systemic toxicity. 
 In 1996 the sodium iodide symporter gene(NIS) 1, 2, was cloned.  Since that time many 
investigators have explored the ability of NIS gene transfer to facilitate targeted radioiodide therapy of 
non thyroidal cancers. As a result, NIS gene transfer has been demonstrated to increase radioactive 
iodine uptake several hundred fold in a variety of tumor systems 3-6. In addition to acting therapeutically 
and arresting tumor cell growth or killing them outright, the use of 131I allows in vivo tumor imaging 3, 7, 5, 
8, 9. The ability to deliver a radio nuclide directly to cancer cells which could then kill those cells, made us 
speculate about the possibility to use this virus encoded gene as a reporter and therapeutic tool to target 
effector cells in the setting of allograft rejection. The aim of the study, therefore, was to analyze the 
effects of iodine 131 after hNIS ex-vivo gene transfer in a rat model of acute allo-rejection. 
Materials and Methods 
 Inbred Lewis rats (300-350g, Harlan®, IN) and Brown-Norway rats (250-300g, Harlan®, IN) were 
used as recipients and donors, respectively, for allogenic abdominal heterotopic heart transplantation. 
Procedures and handling of animals were reviewed and approved by the Institutional Animal Care and 
Use Committee of the Mayo Clinic and Foundation in compliance with “Principles of Laboratory Animal 
Care” formulated by the National Society for Medical Research and the “Guide for the Care and Use of 
Laboratory Animals” prepared by the Institute of Laboratory Animal Resources and published by the 
National Institutes of Health (National Institutes of Health publication No. 86-23, revised 1996). 
 Recombinant Adenovirus Production  
 A replication-deficient human recombinant adenovirus serotype 5 (Ad) construct containing 
human NIS under the control of the CMV promoter (Ad5/CMV/hNIS) was produced in collaboration with 
the Mayo Clinic Vector Production Facility using previously described methods10.  Following plaque 
purification, the recombinant adenovirus Ad5/CMV/NIS was expanded in 293 cells and purified by 
banding on CsCl density gradients, followed by dialysis.  Purified virus was diluted in cold University of 
Wisconsin (UW) solution to a concentration of 10
9 
pfu/ml just prior to ex vivo perfusion of donor hearts.   
 Donor operation 
 Donor hearts were harvested using standard technique as previously described 11. After 
harvesting, the heart was stored in cold UW solution at 4°C. Prior to transplant all hearts were perfused 
with UW solution or UW solution containing Ad-NIS virus using a Langendorff perfusion apparatus as 
perviously described 11.  
 Experimental groups and gene transfer 
Experiment 1 
 Hearts were perfused ex vivo for 30 minutes at 4°C with 5 ml of either UW solution (n=6) or  with 
UW solution containing Ad-hNIS at 1x 109 pfu/ml (n=6) 11. To confirm expression of Ad-NIS all animals 
underwent SPECT/CT imaging of the donor hearts on post-operative day 4 after tail vein injection of 1000 




 Twenty-seven transplants were performed. For group A (n=3) and B (n=6) the donor hearts were 
perfused for 30 minutes at 4°C with 5 ml of UW solution. Donor hearts for groups C, D and E (n=6 animals  
in each group), were perfused with 5 ml of Ad-NIS diluted in UW solution at a concentration of 1x 109 
pfu/ml under the same conditions. Hearts from all groups were then stored in UW solution at 4 C while 
the recipient was prepared. Groups B, D and E were infused by tail vein injection  with 15000 μCi of  131I 
three days after transplant. The remaining animals, group A and C, were injected with 0.1 ml of saline. 
 The status of the transplanted hearts was monitored by palpation and scored on a scale from 0 
(non-beating) to 6 (vigorous, normal contractility). Transplanted hearts were harvested when the 
palpation scores fell to zero. Hearts from animals belonging to group D were harvested electively six days 
after surgery for histologic comparisons to the other groups. 
 Recipient operation 
 Heterotopic transplants were performed using standard techniques 11. All rats received analgesia 
postoperatively (Buprenorphine administered subcutaneously) and recovered with oxygen in a warm 
environment.  
 Imaging with micro-SPECT 
 Micro-SPECT/CT imaging was performed on POD 4 under sedation (intraperitoneal pentobarbital 
50mg/kg). 20 minutes after tail vein injection of  37 MBq of 
123
I.  The dose of infused 
123
I was corrected 
for residual material that remained within the syringe. Micro-SPECT images were obtained under a high-
resolution gamma camera (X-SPECT, Gamma Medica-Ideas Inc., CA) with a low energy high resolution 
parallel hole collimator with 64 projections at a rate of 10s per projection and an acquisition time of 13m 
46s.  CT images were obtained under a circular orbit at a thickness of 50μM per slice under the same 
scanner without moving the animal in between.  This ensured accurate co-registration of the axial CT 
images with the micro-SPECT maps.   
 In Vivo Image Analysis  
 SPECT and CT images were stored and pixel-intensity of the images was quantified as described 
in earlier studies 
12
.  Briefly, the regions of interest (ROI) were defined manually around the heart shadows 
on the reconstructed axial tomographic images  and quantification of 
123
I uptake was performed on the co-
registered micro-SPECT images. Cumulative pixel counts within the defined region of interest (ROI) were 
converted to activity using a conversion factor of 1.63 x 10
-7
 MBq/measured count derived from our 
previous studies 
13, 14
. Values  were expressed as a percentage of the injected dose per gram of heart tissue 
(%ID/g).   
 Measurements were obtained by an independent observer blinded to the origin of the images. 
Following the last imaging procedure, the rats were euthanized by exanguination and the transplanted 
hearts explanted and weighed.  
 Histologic Analysis 
 Under direct visualization full thickness mid-ventricular sections of the explanted hearts were 
collected and processed for routine light microscopy.  Sections of all grafts were reviewed in a blinded 
fashion by an experienced cardiac pathologist. Acute rejection was scored according to the International 
Society for Heart and Lung Transplantation (ISHLT) grading system 
15
. Due to the severity of the changes, 
in addition to using the scoring system, the amount of damaged myocardium involved was quantified as a 
percent of total area examined by a visual estimate. 
 Detection of CD4 and CD8 was determined by immunohistochemistry (IHC).  The paraffin-
embedded (FFPE) samples were deparaffinized with 3 changes of  xylene and rehydrated in a series of 
alcohols (100%, 95%, then 70% EtOH) and rinsed well in running distilled water.  Slides were then placed 
in a preheated 0.1mM EDTA, pH 8.0 retrieval buffer for 30 minutes then cooled in the buffer for 5 
minutes followed by a 5 minute rinse in running distilled water. After heat inactivated epitope retrieval 
(HIER), slides were placed on a DAKO (Carpenteria, CA ) Autostainer for the following procedure (at room 
temperature).  Sections were incubated with 3% H2O2 in ethanol for 5 min. to inactivate the endogenous 
peroxides, then incubated in 1:20 CD4 or CD8 (NCL-CD4-368, Novocastra Laboratories, Newcastle, United 
Kingdom and M7103, DAKO, respectively) for 30 minutes, followed by a rinse with TBST wash buffer.   
Secondary incubation was with DUAL+/HRP labeled polymer (K4061, DAKO) for 15 minutes. The slides 
were rinsed with TBST wash buffer. Sections were then incubated in 3,3’-diaminobenzidine(DAB+)(K3467, 
DAKO) for 5 minutes, counterstained with modified Schmidts’s Hematoxylin for 5 minutes and then 
rinsed for 3 minutes in tap water to blue sections, dehydrated through graded alcohols and cleared in 3 
changes of xylene prior to mounting. 
 
 Statistics 
 T-test analysis was used to compare image intensity between Ad-NIS perfused hearts and 
controls in experiment 1 and to compare daily palpation scores, from POD 0 to POD 6,  between Ad-NIS 
transduced hearts implanted in recipients 131I injected (Group D and E) and controls (Group A, B and C) in 
experiment 2. Graft survival is shown as mean survival time (±SD) and by Kaplan-Meier cumulative 
survival curves. Statistical significance of differences in graft survival between groups A, B, C and E 
(experiment 2) was analyzed using product limit (Kaplan-Meier) survival estimates by Log-Rank statistics. 
A p value of less than 0.05 was considered significant.  
 
Results 
There were no operative deaths in the 33 recipients in the study and no deaths occurred during the 
follow up period. 
 Experiment 1: Gene transfer confirmation  
 All 12 animals underwent SPCT/CT imaging on post-operative day 4 to confirm gene transfer. 
Significantly higher image intensity was noted in the hearts perfused with UW and Ad-NIS (1.0±0.2) 
compared with controls (0.45±0.12) (%ID/g; mean±SD; p<0.05) (Figure 1). These data confirm the gene 
was transferred after ex-vivo perfusion with a solution containing Ad-NIS. 
 Experiment 2:  
Graft Survival and Histology 
 Graft survival was significantly higher in recipients of Ad-NIS transduced donor hearts that were 
injected with 131I (Group E; mean survival 11.3±1.9 days) compared to control transplants without Ad-NIS 
transduction or 131I injection (Group A), recipients treated with 131I but transplanted with hearts lacking 
Ad-NIS perfusion (Group B), or recipients transplanted with Ad-NIS transduced hearts but not injected 
with 131I (Group C) (5.7±0.6, 5.5±1.0 and 5.3±0.8) respectively for groups A, B and C  p< 0.001 (Figure 2A).  
 The range of mean survival of the controls (group A, B and C) was 5.3 to 5.7 days. On the base of 
this finding from POD 0 to POD 6 mean daily palpation score of group A, B and C was compared with 
group D and E. Respect to controls, palpation score was significantly higher from POD 4 in those Ad-NIS 
hearts transplanted into recipients treated with 131I on POD 3 respect to controls (p<0.0001) (Figure 2B). 
 Rejected grafts from groups A, B, C and E, which were explanted when no longer beating, showed  
widespread coagulative  myocyte necrosis,  with hemorrhage and edema.  (Figure 3, left panel). Areas of 
organization were also present in some hearts. There was minimal cellularity and most cells present were 
macrophages. Significant numbers of T cells  were not observed (data not shown). In  contrast hearts 
from group D (Ad-NIS perfused hearts transplanted into recipients 131I injected on POD 3),  which were 
still beating at the time of elective explant (POD 6), had a palpation score of 3.7±1.2 ( mean±SD).  
Histologically these hearts showed focal areas of coagulative necrosis, but no cellular infiltrates. The 
average percentage of myocardial damage of group D grafts was 60.8%, significantly lower than the 
degree of rejection observed in all the other transplanted hearts (p<0.05) (Figure 3, right panel). 
Discussion 
 This study demonstrates that adeno-mediated myocardial expression of the hNIS gene coupled to 
131I injection can prolonged cardiac graft survival in a rat allo-transplantation model. This finding is 
confirmed by a significantly higher palpation score of Ad-NIS perfused hearts after 131I  injection respect 
to controls (either no Ad-NIS +/- 131I or Ad-NIS transfected hearts + no 131I ) that showed a progressive 
decline to 0 of the contractility within 6 days after transplant. The palpation score, as a direct measure of 
cardiac vitality and effective contractility, proved to be a reliable and convenient test for the definition of 
the endpoint for graft survival with no variability or bias in the evaluations of independent observers. 
 The histology of grafts perfused with solution of UW and Ad-NIS, in animals that were 131I injected 
on POD 3, showed a lower percentage of myocardial damage compared to the controls. The myocardial 
damage observed in these hearts consisted predominantly of coagulative necrosis with hemorrhage and 
edema. There was minimal cellularity and so rejection could not be graded according to the ISHLT 
criteria.  This is likely due to the fact that these animals were not immunosupressed and the features we 
observed were those of an endstage rejection process. To our knowledge this is the first time that NIS-
targeted 131I therapy has been utilized in the setting of cardiac transplantation. 
 The effectiveness of NIS as non-invasive reporter gene has  been validated in  several studies in 
tumor models of gene transfer16, 17. In a previous study from our group we demonstrated that hNIS is an 
excellent reporter gene for the transplanted heart. The expression level of hNIS can be accurately and 
non-invasively monitored by serial radioisotopic SPECT imaging. In addition hNIS gene transfer permits 
sequential real-time detection and quantification of reporter gene expression in the transplanted heart 
(manuscript submitted).  
 With the experience obtained with non-invasive radioiodine imaging for quantitation of NIS 
reporter gene expression and the proven utility of NIS-targeted radionuclide in cancer therapy we think 
that this virus-encoded gene could be effectively used as both a reporter and a therapeutic gene in 
cardiac transplantation.  
 The administration of iodine 131 in the millicurie quantities (15 mCi), as were used in this study, 
raises a question regarding radiation dose and its effects on the cardiac tissue. Our study showed that 
cardiac tissues accumulated about 1% of the injected dose per gram of tissue. There are several factors 
that contribute to the cardiac radiation dose, including the frequency of Ad-NIS transduction in the 
tissue, the rate of  131I uptake and release from the heart,  and the decay rate of 131I to name a few. The 
biological half-life of 131I shows substantial variation between tissues  with an average of approximately 
10h 6, 16, 18-24. When the decay rate of 131I (196 hours) is included this average biological half life decreases 
to 9.6 hours. As recommended by the Medical Internal Radiation Dosimetry Committee using the 
equation D = 1.44AS where D is dose in rad, A is accumulated activity in microcuries, and S is the amount 
of radiation deposited in a target tissue 21, we estimate the radiation dose for the heart to be 56.9 rad 
(0.57 Gy) after 20 minutes from injection, which is well below the dose documented to be a threshold for 
radiation side effects on the heart 25. Thus, a higher cardiac dose of iodine 131 could be used without 
direct radiation induced damage to the heart. However in the rat a whole body dose of 15 mCi is the 
maximum that can be administered before having complications due to 131I induced gastritis 26. Within 
the time frame of our study none of the rats exhibited weight loss and the histology of other organs (liver 
kidney lung and spleen) was normal. This suggests for this model that a higher cardiac dose of 131I could 
only be achieved through more efficient Ad virus transduction of the heart during perfusion. 
Study limitations 
 The variability of NIS expression could represent a disadvantage of the Ad vector system that is 
well recognized. Ad dependence on Coxsackie virus and adenovirus receptor (CAR) to transfect cells 
contributes to the unpredictability and inefficiency of this system. In addition adenoviral vectors have 
been shown to suffer a number of concerns including induction of an inflammatory response and a 
limited duration of transgene expression. Most studies using adenoviral mediated gene transfer have 
reported a peak of gene expression around day 7 followed by total loss of gene expression between 3 to 
4 weeks after gene delivery27-29. However, the need for immunosuppression in transplantation may 
modify this immune response and facilitate prolonged gene expression. Alternatively it would be possible 
to use recombinant adeno-associated virus (rAAV) vectors. These vectors have been shown to result in 
prolonged transgene expression without inflammation 30-35. A long acting vector could allow to treat in 
the same way also further episodes of rejection.   
 This is not a dose/response study. It would be necessary, especially in a bigger animal model, to 
define the safest and most effective dose of iodine 131 to inject. 
 The mechanism by which iodine 131 after hNIS ex-vivo gene transfer prolonged allograft survival 
is not clear and still need to be analyzed in this model. We believe that there are three possible 
pathways, first a direct immunosuppressive effect induced by the concentration of the radionuclide in 
the transplanted heart favoured by the presence of genetically transferred hNIS, second an indirect effect 
through radiation inducible promoters that modulate the immune response activating cytoprotective and 
immunomodulatory molecules, third a combination of the two mechanisms together.   
 In conclusion this study indicates that 131I, after NIS gene transfer, can effectively prolong graft 
survival. This finding provides the rationale to explore the use of gene transfer in combination with other 
therapeutic modalities as an approach for treating acute rejection. Further study is required to determine 
the mechanism of this effect and its potential for clinical application. 
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Figure 1 Micro-SPECT antero-posterior view of the abdomen showing the transplanted heart on POD 4. 
Image intensity of UW+Ad-NIS perfused hearts (left) was significantly higher than controls (right), 1.0±0.2 
vs 0.45±0.12 respectively (%ID/g; mean±SD; p<0.05). The “hot spot” corresponds to the position of the 
transplanted heart (*). The “hot spot” above the transplanted heart corresponds to the 
123
I concentration 
in the stomach due to the inherent presence of NIS in the gastric mucosa. The ROI were defined manually 
around the heart shadows on the reconstructed axial tomographic images in all sections in which the 
heart was visualized, and quantification performed on the co-registered micro-SPECT images. This 
ensured accurate co-registration of the axial CT images with the micro-SPECT maps. 
Figure 2 A. Prolonged survival of cardiac allografts after ex-vivo perfusion with solution of UW+Ad-NIS 
and 131I injection on POD 3 (Group E) (p<0.0001 vs all the other grafts grouped together, Kaplan-Meier 
log-rank statistical analysis). B Transplanted hearts were monitored daily by palpation and scored on a 
scale from 0 (non-beating) to 6 (vigorous, normal contractility). The mean value with the standard 
deviation is given for controls (white bars: group A, B, and C) and Ad-NIS transduced donor hearts in 
recipients that were injected with 131I on POD 3 (black bars: group D and E). Palpation score was 
significantly higher in group D and E respect to the controls (*p<0.0001). POD: post-operative day.  
Figure 3 Representative pathology of grafts. The left panel shows representative histology from groups A, 
B, C and E. The myocardium has marked coagulative necrosis with hemorrhage, edema and organization. 
There is minimal inflammation and most cells present are macrophages. These features are consistent 
with end stage rejection. The right panel shows hearts from Group D (those perfused with a solution of 
UW and Ad-NIS + 131I injection on POD 3). There are only focal areas of coagulative necrosis (arrows), but 
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